MONTREAL--(BUSINESS WIRE)--March 22, 2006--Ambrilia Biopharma Inc. (formerly Procyon Biopharma Inc.) (TSX:AMB), a biotechnology company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today its fiscal 2005 results and the appointment of three new members to its Board of Directors.
